A Signaling Polypeptide Derived from an Innate Immune Adaptor Molecule Can Be Harnessed as a New Class of Vaccine Adjuvant

Kobiyama, Kouji; Takeshita, Fumihiko; Ishii, Ken J.; Koyama, Shohei; Aoshi, Taiki; Akira, Shizuo; Sakaue-Sawano, Asako; Miyawaki, Atsushi; Yamanaka, Yuko; Hirano, Hisashi; Suzuki, Koichi; Okuda, Kenji

doi:10.4049/jimmunol.182.3.1593

Cited by 16 publications

(18 citation statements)

References 37 publications

(35 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The TBK-1-activating N-CARD of IPS-1 improved humoral and cellular responses to protein vaccines (18). The eRNA ligand developed here also signals through IPS-1 but is superior for immunostimulation since, unlike protein ligands, it will not limit repeat usage of the DNA vaccine vector.…”

Section: Discussionmentioning

confidence: 99%

“…Consistent with this, the TBK-1-activating N-terminal caspase recruitment domain (N-CARD) of IPS-1 had adjuvant activity to improve humoral and cellular responses to protein vaccines (18). Interestingly, induction of adaptive immune responses to influenza virus or lymphocytic choriomeningitis virus infection required TLR not RLH signaling (reviewed in reference 21).…”

mentioning

confidence: 82%

See 1 more Smart Citation

Coexpressed RIG-I Agonist Enhances Humoral Immune Response to Influenza Virus DNA Vaccine

Luke

Simon

Söderholm

et al. 2011

J Virol

View full text Add to dashboard Cite

Section: Discussionmentioning

confidence: 99%

mentioning

confidence: 82%

Coexpressed RIG-I Agonist Enhances Humoral Immune Response to Influenza Virus DNA Vaccine

Luke

Simon

Söderholm

et al. 2011

J Virol

View full text Add to dashboard Cite

“…These include a family of RNA helicase receptors referred to as RLRs: RIG-1, melanoma differentiation factor 5 (MDA-5) and laboratory of genetics and physiology-2 (LGP2) [19]. Unlike TLRs that recognize viral The findings of this study also provide insights that may prove useful in the rational design of immunomodulatory agents, such as the use of constitutively active signalling of the innate immune response [39].…”

Section: Rig-like Helicases (Rlhs)mentioning

confidence: 96%

TLR, NLR Agonists, and Other Immune Modulators as Infectious Disease Vaccine Adjuvants

Higgins

Mills

2010

Curr Infect Dis Rep

View full text Add to dashboard Cite

Vaccines based on attenuated or killed viruses and bacteria are highly effective in preventing infection with a range of pathogens, but can have safety issues. Therefore, there is a move towards subunit vaccines based on recombinant proteins or naked DNA. However, protein subunit vaccines are typically poorly immunogenic when administered alone and therefore require co-administration with adjuvants to boost the immune response.

show abstract

“…RLHs trigger cellular signaling through an adaptor molecule, IFNpromoter stimulator 1 (IPS-1, also known as MAVS/VISA/ Cardif) containing a critical signaling element, CARD [45]. We have recently generated a novel type of vaccine adjuvant N'-CARD, which is a synthetic fusion molecule consisting of the nuclear localization signal from histone H2B and the CARD from IPS-1 [46]. N'-CARD, when expressed intracellularly, interacts with intrinsic nuclear DNA helicase II, leading to strong type I IFN production.…”

Section: Signal Transducers Of the Innate Immune Systemmentioning

confidence: 99%

Application of Innate Immune Molecules for a New Class of Drugs: Infection, Inflammation and Beyond

Kimura¹,

Suzuki

Landek-Salgado

et al. 2011

EMIDDT

View full text Add to dashboard Cite

The innate immune system plays an important role systemically and locally in infectious and inflammatory diseases. Vaccines, vaccine adjuvants and anti-inflammatory drugs were developed by understanding mechanisms of the innate immune system and causative factors of infection and inflammatory diseases. Pattern-recognition receptors, such as Toll-like receptors, retinoic acid-inducible gene I (RIG-I)-like helicases and nucleotide-binding oligomerization domain(NOD)-like receptors, and their downstream signals have great potential as targets of therapeutics because they are involved in numerous diseases. Furthermore, proteolytic systems such as autophagy and immunoproteasomes play important roles in the innate immune system, making them potential therapeutic targets also. By taking advantage of the immune system, humankind has made a great effort to develop new therapeutic and preventive medicines. Accordingly, we have reported several studies on the development of vaccines and adjuvants based on novel mechanistic strategies. Additionally, we have elucidated the mechanism underlying an interaction between innate immunity and the endocrine system. This review introduces the possible use of innate immune molecules for the development of immunomodulatory drugs and the involvement of the immune system in endocrine metabolic diseases to discuss future applications of innate immune molecules to therapeutics of various inflammatory diseases.

show abstract

A Signaling Polypeptide Derived from an Innate Immune Adaptor Molecule Can Be Harnessed as a New Class of Vaccine Adjuvant

Cited by 16 publications

References 37 publications

Coexpressed RIG-I Agonist Enhances Humoral Immune Response to Influenza Virus DNA Vaccine

Coexpressed RIG-I Agonist Enhances Humoral Immune Response to Influenza Virus DNA Vaccine

TLR, NLR Agonists, and Other Immune Modulators as Infectious Disease Vaccine Adjuvants

Application of Innate Immune Molecules for a New Class of Drugs: Infection, Inflammation and Beyond

Contact Info

Product

Resources

About